cemiplimab
Sign in to saveCemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
Clinical Trials
169 registered- PHASE2ACTIVE_NOT_RECRUITINGTesting the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated LiposarcomaAlliance for Clinical Trials in Oncology · NCT05694871
- PHASE2RECRUITINGA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)Regeneron Pharmaceuticals · NCT06465329
- PHASE2ACTIVE_NOT_RECRUITINGA Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryRegeneron Pharmaceuticals · NCT06161441
- PHASE1/PHASE2WITHDRAWNBIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell LymphomaAHS Cancer Control Alberta · NCT05538988
- PHASE2COMPLETEDCemiplimab for Secondary AngiosarcomasRadboud University Medical Center · NCT04873375
- PHASE1RECRUITINGA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.OncoNano Medicine, Inc. · NCT06022029
~5 min read
Article
6 sectionsContents
- Medical uses
- Adverse effects
- Mechanism of action
- History
- References
- External links
Cemiplimab, sold under the brand name Libtayo, is a monoclonal antibody medication used for the treatment of squamous cell skin cancer. Cemiplimab belongs to a class of drugs that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway.
The most common side effects include fatigue, rash, diarrhea, musculoskeletal pain, and nausea.
Connections
monoclonal antibody
Entity
fusion protein
Entity
programmed cell death 1
Protein
dinutuximab
Entity
lumiliximab
Entity
human
Entity
World Health Organization
Entity
immunity
Entity
public domain
Entity
digital object identifier
Entity
leukemia
Entity
chemical formula
Entity
thyroid gland
Entity
hepatitis
Entity
lymphatic system
Entity
molar mass
Entity
Q180686
Entity
antigen
Entity
lymphoma
Entity
hypothyroidism
Entity